Kodiak Sciences: Anti-VEGF Could Win Nicely On Retinal Disorders

Company Overview - Kodiak Sciences (NASDAQ: KOD) is a biopharmaceutical company focused on developing treatments for retinal diseases that can lead to blindness [1] - The company utilizes a novel Antibody Biopolymer Conjugate Design (ABCD) platform, which aims to create drugs with enhanced durability and efficacy, allowing for fewer doses required for treatment [1] Pipeline and Development - Kodiak Sciences has an active pipeline that includes various candidates targeting retinal diseases, although specific details on the pipeline are not provided in the text [1]